RTP Mobile Logo
Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Non-Small Cell Lung Cancer
Released July 2018

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs Matthew D Hellmann, Corey J Langer, Geoffrey R Oxnard, Martin Reck and Alice Shaw. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

    Lung cancer is a devastating disease with broad-reaching impact on public health as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In the year 2018, it is estimated that approximately 234,030 individuals will be diagnosed and 154,050 will die from the disease. Of importance, despite the many advances over the past few decades related to surgery, radiation therapy and chemotherapy, death rates attributable to lung cancer have remained relatively unchanged. Today, however, many have renewed optimism that these trends have already started to change as recent research advances have led to an explosion in lung cancer genetic and biologic knowledge among scientists and clinicians working in this area of cancer medicine. Over the past several years major clinical trials in NSCLC have witnessed a host of promising successes, many of which are already being operationalized in clinical practice. Even so, these achievements will doubtlessly continue to be dissected in the upcoming years and will further challenge the collective understanding of the biology and optimal management of this disease.

    These proceedings from a CME symposium during the 2018 ASCO Annual Meeting explore the most significant therapeutic advances in the field of NSCLC by using the perspectives of leading lung cancer experts on challenging cases and questions submitted by clinicians in the community to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help medical oncologists and other allied healthcare professionals find answers to the individualized questions and concerns that they frequently encounter and in turn provide high-quality cancer care.


    • Appreciate available Phase III data documenting the benefit of sequential anti-PD-L1 therapy after completion of chemoradiation therapy for Stage III NSCLC, and consider the role of durvalumab for appropriate patients.
    • Recognize available and emerging research information validating the utility of diagnostic assays designed to measure EGFR, ALK, ROS1, BRAF and PD-L1 status, assess which testing platforms should be used and appropriately employ the results of these assessments to individualize first- and later-line therapy for patients with metastatic NSCLC.
    • Recall the results from the Phase III FLAURA trial and consider how, if at all, these findings and the subsequent FDA approval of osimertinib as first-line therapy affect current or future therapy for patients with EGFR mutations.
    • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
    • Review published research documenting the safety and efficacy of anti-PD-1/PD-L1 antibodies used as monotherapy or in combination with chemotherapy with or without anti-VEGF therapy for newly diagnosed metastatic NSCLC.
    • Consider available Phase III data comparing nivolumab in combination with ipilimumab to chemotherapy as first-line treatment for patients with NSCLC and a high tumor mutational burden.
    • Describe ongoing research to assist in the identification of additional biomarkers, tumor characteristics or other clinical features that are indicative of response to immune checkpoint inhibitors in patients with NSCLC.
    • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic and systemic therapies for NSCLC, and counsel appropriate patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Matthew D Hellmann, MD
    Medical Oncologist
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Janssen Biotech Inc, Merck, Novartis.

    Corey J Langer, MD
    Director of Thoracic Oncology
    Abramson Cancer Center
    Professor of Medicine
    Perelman School of Medicine
    University of Pennsylvania
    Vice Chair, Radiation Therapy Oncology Group
    Philadelphia, Pennsylvania

    Advisory Committee: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advantagene Inc, Ariad Pharmaceuticals Inc, GlaxoSmithKline, Inovio Pharmaceuticals Inc, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc.

    Geoffrey R Oxnard, MD
    Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, DropWorks CEI, GRAIL Inc, Guardant Health Inc, Ignyta Inc, Inivata, Loxo Oncology Inc.

    Martin Reck, MD, PhD
    Head of Department of Thoracic Oncology
    Head of Clinical Trial Department
    LungenClinic Grosshansdorf
    Grosshansdorf, Germany

    Consulting Agreements and Contracted Research: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc.

    Alice Shaw, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Center for Thoracic Cancers
    Massachusetts General Hospital
    Boston, Massachusetts

    Advisory Committee: Blueprint Medicines; Consulting Agreements: Ariad Pharmaceuticals Inc, Blueprint Medicines, Daiichi Sankyo Inc, EMD Serono Inc, Foundation Medicine, Genentech, Ignyta Inc, KSQ Therapeutics, Loxo Oncology Inc, Natera Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Foundation Medicine, Genentech, Merck and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: July 2018
    Expiration date: July 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):


Long-Term Management of Non-Small Cell Lung Cancer (NSCLC) in Patients with an Activating EGFR Mutation

Recent Treatment Advances for Patients with ALK/ROS1- and BRAF-Positive NSCLC; Other Targets with the Potential to Affect Treatment Decision-Making

Optimal Integration of Immune Checkpoint Inhibition into Clinical Decision-Making for Patients with Locally Advanced NSCLC

Current Role of Immune Checkpoint Inhibitors in Combination with Chemotherapy and/or Anti-angiogenic Agents in the Treatment of Metastatic Disease

  • Potential Role of Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies in Combination; Future Directions for Clinical Research
  • Select Publications